Evidence map›Paper›PMID 39857693›Full record

ReviewBiomedicines2025

Non-Invasive Detection of Tumors by Volatile Organic Compounds in Urine.

Tomoaki Hara, Sikun Meng, Yasuko Arao, Yoshiko Saito, Kana Inoue, Aya Hasan Alshammari, Hideyuki Hatakeyama, Eric di Luccio, Andrea Vecchione, Takaaki Hirotsu and 1 more

Abstract readReview
In one paragraph

Review in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tomoaki HaraDepartment of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Suita, Yamadaoka 2-2, Osaka 565-0871, Japan.
Sikun MengDepartment of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Suita, Yamadaoka 2-2, Osaka 565-0871, Japan.
Yasuko AraoDepartment of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Suita, Yamadaoka 2-2, Osaka 565-0871, Japan.
Yoshiko SaitoDepartment of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Suita, Yamadaoka 2-2, Osaka 565-0871, Japan.
Kana InoueDepartment of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Suita, Yamadaoka 2-2, Osaka 565-0871, Japan.
Aya Hasan AlshammariHirotsu Bio Science Inc., Chiyoda-Ku, Tokyo 102-0094, Japan.
Hideyuki HatakeyamaHirotsu Bio Science Inc., Chiyoda-Ku, Tokyo 102-0094, Japan.
Eric di LuccioHirotsu Bio Science Inc., Chiyoda-Ku, Tokyo 102-0094, Japan.ORCID 0000-0002-2256-2157
Andrea VecchioneDepartment of Clinical and Molecular Medicine, University of Rome "Sapienza", Santo Andrea Hospital, Via di Grottarossa, 1035-00189 Rome, Italy.ORCID 0000-0002-5497-6856
Takaaki HirotsuHirotsu Bio Science Inc., Chiyoda-Ku, Tokyo 102-0094, Japan.ORCID 0009-0009-3276-6020
Hideshi IshiiDepartment of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Suita, Yamadaoka 2-2, Osaka 565-0871, Japan.ORCID 0000-0002-0632-6517

Funding

AMED nos. JP23ym0126809 and JP24ym0126809Ministry of Education, Culture, Sports, Science and Technology nos. 19K22658, 20H00541, 21K19526, 22H03146, 22K19559, 23K19505, 23K18313, 23KK0153, 24K22144, and 16H06279 (PAGS)Princess Takamatsu Cancer Research Fund 2023
6 · The paper itself

Abstract

Cancer is one of the major causes of death, and as it becomes more malignant, it becomes an intractable disease that is difficult to cure completely. Therefore, early detection is important to increase the survival rate. For this reason, testing with blood biomarkers is currently common. However, in order to accurately diagnose early-stage cancer, new biomarkers and diagnostic methods that enable highly accurate diagnosis are needed. This review summarizes recent studies on cancer biomarker detection. In particular, we focus on the analysis of volatile organic compounds (VOCs) in urine and the development of diagnostic methods using olfactory receptors in living organisms. Urinary samples from cancer patients contain a wide variety of VOCs, and the identification of cancer specific compounds is underway. It has also been found that the olfactory sense of organisms can distinguish cancer-specific odors, which may be applicable to cancer diagnosis. We explore the possibility of novel cancer biomarker candidates and novel diagnostic methods.

Indexed as

biomarkerscancerdiagnosticsolfactory receptorsvolatile organic compounds

Identifiers

PMID39857693
PMCPMC11762175

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.